THE COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA TREATMENT: A SYSTEMATIC REVIEW

被引：0
|
作者：
Li, H. [1 ]
Ren, J. [1 ]
Yu, X. [2 ]
机构：
[1] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
[2] Xian Janssen Pharmaceut Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A670 / A670
页数：1
相关论文
共 50 条
  • [21] Pharmacoeconomics of long-acting risperidone: Results and validity of cost-effectiveness models
    Alan Haycox
    PharmacoEconomics, 2005, 23 : 3 - 16
  • [22] A COST-EFFECTIVENESS ANALYSIS OF THE LONG-ACTING ANTISPYCHOTIC DRUGS PALIPERIDONE PALMITATE, OLANZAPINE PAMOATE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN FINLAND
    Einarson, T. R.
    Pudas, H.
    Zilbershtein, R.
    Jensen, R.
    Nielsen, A. T.
    Piwko, C.
    Hemels, M.
    Vincente, C.
    VALUE IN HEALTH, 2012, 15 (07) : A337 - A338
  • [23] Cost effectiveness of long-acting risperidone in Sweden
    Hensen M.
    Heeg B.
    Lthgren M.
    Van Hout B.
    Applied Health Economics and Health Policy, 2010, 8 (5) : 327 - 341
  • [24] Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA
    Natalie Christine Edwards
    Julie C. Locklear
    Marcia F. T. Rupnow
    Ronald J. Diamond
    PharmacoEconomics, 2005, 23 : 75 - 89
  • [25] Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA
    Edwards, NC
    Locklear, JC
    Rupnow, MFT
    Diamond, RJ
    PHARMACOECONOMICS, 2005, 23 (Suppl 1) : 75 - 89
  • [26] Cost effectiveness analysis of long-acting risperidone injection compared with olanzapine and fluphenazine decanoate in patients with schizophrenia
    Baca, E
    Bobes, J
    Cañas, F
    Leal, C
    Salvador, L
    Rubio, M
    Magaz, S
    Badía, X
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S238 - S238
  • [27] Long term benefits of treatment with risperidone long-acting injection in patients with schizophrenia
    Turner, MS
    Urquhart, E
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S399 - S399
  • [28] Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis
    Diana De Graeve
    Ann Smet
    Angelika Mehnert
    Sue Caleo
    Houda Miadi-Fargier
    Guillermo Jasso Mosqueda
    Damien Lecompte
    Joseph Peuskens
    PharmacoEconomics, 2005, 23 : 35 - 47
  • [29] Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis
    De Graeve, D
    Smet, A
    Mehnert, A
    Caleo, S
    Miadi-Fargier, H
    Mosqueda, GJ
    Lecompte, D
    Peuskens, J
    PHARMACOECONOMICS, 2005, 23 (Suppl 1) : 35 - 47
  • [30] COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION IN THE TREATMENT OF NON-ADHERENCE PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
    Ascher-Svanum, H.
    Furiak, N. M.
    Klein, R. W.
    Montgomery, W.
    Smolen, L. J.
    Lawson, A. H.
    Conley, R. R.
    VALUE IN HEALTH, 2009, 12 (03) : A176 - A176
12345